Human γδ T-Cell Control of Mucosal Immunity and Inflammation
Open Access
- 7 May 2018
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 9, 985
Abstract
Human γδ T-cells include some of the most common “antigen-specific” cell types in peripheral blood and are enriched yet further at mucosal barrier sites where microbial infection and tumors often originate. While the γδ T-cell compartment includes multiple subsets with highly flexible effector functions, human mucosal tissues are dominated by host stress-responsive Vδ1+ T-cells and microbe-responsive Vδ2+ T-cells. Widely recognized for their potent cytotoxicity, emerging data suggest that γδ T-cells also exert strong influences on downstream adaptive immunity to pathogens and tumors, in particular via activation of antigen-presenting cells and/or direct stimulation of other mucosal leukocytes. These unique functional attributes and lack of MHC restriction have prompted considerable interest in therapeutic targeting of γδ T-cells. Indeed, several drugs already in clinical use, including vedolizumab, infliximab, and azathioprine, likely owe their efficacy in part to modulation of γδ T-cell function. Recent clinical trials of Vδ2+ T-cell-selective treatments indicate a good safety profile in human patients, and efficacy is set to increase as more potent/targeted drugs continue to be developed. Key advances will include identifying methods of directing γδ T-cell recruitment to specific tissues to enhance host protection against invading pathogens, or alternatively, retaining these cells in the circulation to limit peripheral inflammation and/or improve responses to blood malignancies. Human γδ T-cell control of mucosal immunity is likely exerted via multiple mechanisms that induce diverse responses in other types of tissue-resident leukocytes. Understanding the microenvironmental signals that regulate these functions will be critical to the development of new γδ T-cell-based therapies.Keywords
Funding Information
- Wellcome Trust (AC1120IF06)
- Crohn’s and Colitis UK (M/13/5)
- Crohn’s in Childhood Research Association
- Medical Research Council (MR/N023145/1, MR/R008302/1)
This publication has 96 references indexed in Scilit:
- Phosphoantigen/IL2 Expansion and Differentiation of Vγ2Vδ2 T Cells Increase Resistance to Tuberculosis in Nonhuman PrimatesPLOS Pathogens, 2013
- Dynamic migration of γδ intraepithelial lymphocytes requires occludinProceedings of the National Academy of Sciences, 2012
- γδ intraepithelial lymphocytes are essential mediators of host–microbial homeostasis at the intestinal mucosal surfaceProceedings of the National Academy of Sciences, 2011
- Infliximab Induces Clonal Expansion of γδ-T Cells in Crohn's Disease: A Predictor of Lymphoma Risk?PLOS ONE, 2011
- Epithelial decision makers: in search of the 'epimmunome'Nature Immunology, 2010
- Phenotype and functional changes of Vγ9/Vδ2 T lymphocytes in Behçet's disease and the effect of infliximab on Vγ9/Vδ2 T cell expansion, activation and cytotoxicityArthritis Research & Therapy, 2010
- Antigen-specific Vγ2Vδ2 T effector cells confer homeostatic protection against pneumonic plaque lesionsProceedings of the National Academy of Sciences, 2009
- A Rapid Crosstalk of Human γδ T Cells and Monocytes Drives the Acute Inflammation in Bacterial InfectionsPLOS Pathogens, 2009
- Peripheral blood monocytes are responsible for γδ T cell activation induced by zoledronic acid through accumulation of IPP/DMAPPBritish Journal of Haematology, 2008
- Small intestinal CD8+TCRγδ+NKG2A+ intraepithelial lymphocytes have attributes of regulatory cells in patients with celiac diseaseJournal of Clinical Investigation, 2008